Tanvex BioPharma, Inc. (TWSE: 6541)
Health Care · Biotechnology · KY
NT$33.95
+14.70% today · -46.8% 1Y
Tanvex BioPharma, Inc. (TWSE: 6541) operates in the Biotechnology industry within the Health Care sector. The company is valued at $281.36M and employs 215 people.
Over the last twelve months the share price has lost 46.8%, trading between 29.60 and 68.00.
Tweenvest scores Tanvex BioPharma, Inc. across four factors: quality 36/100, value 48/100, growth 100/100. Its strongest factor is growth.
6541 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $281.36M
- Revenue (TTM)
- $20.67M
- P/E
- —
- EPS
- -5.59
- Dividend yield
- —
- Beta (5Y)
- 0.20
- 52-week high
- NT$68.00
- 52-week low
- NT$29.60
- Avg volume (3M)
- —
- Shares outstanding
- 264.99M
- Employees
- 215
- Next earnings
- —
About Tanvex BioPharma, Inc.
Tanvex BioPharma, Inc., originally known as Ruenvex Biotech, Inc., is a biopharmaceutical company founded in 2013 and based in George Town, Cayman Islands. The firm specializes in the investigation, creation, production, and sale of biosimilar medicines, with its operations spanning Taiwan and the United States. Its core mission involves developing biosimilars aimed at treating severe conditions like neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. The company's robust product portfolio includes TX01 and TX-05, both of which have successfully completed Phase III clinical trials. Additionally, TX-04 and TX-16 are currently undergoing Phase I clinical trials, while TX-52 and other potential therapies are in the pre-clinical development stage.
- ISIN
- KYG8676P1037
- Founded
- 2011
- Listed since
- Aug 13, 2015
- Exchange
- Taiwan Stock Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| X4 Pharmaceuticals, Inc.NasdaqCM: XFOR | $288.52M | $2.91 | +2.83% |
| CytoDyn Inc.OTCPK: CYDY | $287.21M | $0.20 | -11.89% |
| Eurobio Scientific Société anonymeENXTPA: ALERS | $284.09M | €25.30 | +0.40% |
| Abeona Therapeutics Inc.NasdaqCM: ABEO | $282.49M | $4.94 | -1.79% |
| Rocket Pharmaceuticals, Inc.NasdaqGM: RCKT | $281.02M | $2.56 | 0.00% |
| AIM Vaccine Co., Ltd.SEHK: 6660 | $280.55M | HK$1.80 | +6.85% |
| Clinuvel Pharmaceuticals LimitedASX: CUV | $279.41M | AU$7.94 | +0.13% |
| Larimar Therapeutics, Inc.NasdaqGM: LRMR | $278.70M | $2.81 | +5.24% |
Figures last refreshed Oct 11, 2026.